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Abstract 
B chronic lymphocytic leukaemia (B-CLL) is a disease with an enormously 
heterogeneous prognosis. Due to lack of effective treatments and the 
heterogeneity in its course, B-CLL has remained largely incurable. In the last 
two decades a number of biological markers have been recognised as 
prognostic parameters to replace clinical staging, chief among them is ZAP-70 
(a T-cell cytoplasmic tyrosine protein) albeit without a full understanding of the 
mechanism involved. 
 
The aim of this thesis was to identify reliable prognostic factors that could be 
used in the management of B-CLL patients. Seventy-six B-CLL patients were 
studied over 30 months using a random stratified method of sampling, 
whereby adult B-CLL patients were recruited at different stages of the 
disease. Retrospective studies enabled some patients to be studied for up to 
192 months. ZAP-70 expression was demonstrated in some B-CLL cells and 
was examined for possible phosphorylation following B-CLL cells stimulation, 
implying its involvement in cell signalling. Through the use of a novel method 
developed during the present study, B-CLL cells were stimulated via the 
SDF1-α-CD184 signalling pathway resulting in ZAP-70 phosphorylation. Its 
expression and phosphorylation was investigated alongside other prognostic 
factors and also correlated with B-CLL progression. More importantly, this 
study demonstrated that ZAP-70 positive cells are more responsive to signals 
derived from their surrounding environment, such as SDF-1α. 
 
In conclusion ZAP-70, CD38, and CD23 expressions together with IgVH gene 
mutational status were confirmed as indicators of poor prognosis. Response 
to external stimuli by some B-CLL cells, resulting in ZAP-70 phosphorylation 
represents the most novel aspect of this thesis and demonstrates ZAP-70 
involvement in B-CLL signalling. Additionally, raised NK: B-CLL and T: B-CLL 
cell ratios were identified as good modifiable variable predictors of time to 
treatment that could be used for monitoring and therapeutic purposes. Since 
B-CLL is an incurable disease, the identification of prognostic factors could 
help in deciding the best time for intervention in B-CLL patients. 
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